Samson Clinical Completes Enrollment for Landmark Male Pattern Hair Loss Study

Samson Clinical has reached a significant milestone in its efforts to develop a new treatment for male pattern hair loss, also known as androgenetic alopecia (AGA). The company has concluded participant enrollment for its Phase III clinical trial evaluating the efficacy and safety of sublingual (under-the-tongue) minoxidil.

The randomized, multi-center, placebo-controlled study aims to assess the effectiveness of this novel formulation of the well-known hair loss medication. Subjects were assigned in a one-to-one ratio to receive either the sublingual minoxidil or a placebo. With recruitment now complete, Samson expects to release the initial results of the 24-week trial in mid-2026.

AGA is the primary cause of hair loss, affecting up to 80% of men over the course of their lives. Samson founder Professor Rodney Sinclair noted that the rapid enrollment in this trial reflects the strong unmet need among men for safe and effective hair loss treatments that do not have undesirable side effects. If successful, the sublingual minoxidil could become the first new approved medication for male pattern hair loss in this century.